Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis
- 1 July 2008
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 295 (1), L178-L185
- https://doi.org/10.1152/ajplung.00009.2008
Abstract
Earlier work from this laboratory showed that local generation of angiotensin (ANG) II is required for the pathogenesis of experimental pulmonary fibrosis and that ANG peptides are expressed robustly in the lungs of patients with idiopathic pulmonary fibrosis (IPF). Angiotensin converting enzyme-2 (ACE-2) degrades the octapeptide ANG II to form the heptapeptide ANG1-7 and thereby limits ANG II accumulation. On this basis, we hypothesized that ACE-2 would be protective against experimental lung fibrogenesis and might be downregulated in human and experimental lung fibrosis. In lung biopsy specimens from patients with IPF, ACE-2 mRNA and enzyme activity were decreased by 92% ( P < 0.01) and 74% ( P < 0.05), respectively. ACE-2 mRNA and activity were also decreased similarly in the lungs of bleomycin-treated rats and C57-BL6 mice. In mice exposed to low doses of bleomycin, lung collagen accumulation was enhanced by intratracheal administration of either ACE-2-specific small interfering RNAs (siRNAs) or the peptide DX600, a competitive inhibitor of ACE-2 ( P < 0.05). Administration of either ACE-2 siRNA or DX600 significantly increased the ANG II content of mouse lung tissue above the level induced by bleomycin alone. Coadministration of the ANG II receptor antagonist saralasin blocked the DX600-induced increase in lung collagen. Moreover, purified recombinant human ACE-2, delivered to mice systemically by osmotic minipump, attenuated bleomycin-induced lung collagen accumulation. Together, these data show that ACE-2 mRNA and activity are severely downregulated in both human and experimental lung fibrosis and suggest that ACE-2 protects against lung fibrogenesis by limiting the local accumulation of the profibrotic peptide ANG II.This publication has 27 references indexed in Scilit:
- Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosisJournal of Hepatology, 2007
- Liver fibrosis: a balance of ACEs?Clinical Science, 2007
- Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lungJournal of Cellular Biochemistry, 2007
- Downregulation of angiotensin converting enzyme II is associated with pacing‐induced sustained atrial fibrillationFEBS Letters, 2007
- Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHRPhysiological Genomics, 2006
- Distinct roles for ANG II and ANG-(1–7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytesAmerican Journal of Physiology-Cell Physiology, 2006
- Essential Roles for Angiotensin Receptor AT1a in Bleomycin-Induced Apoptosis and Lung Fibrosis in MiceThe American Journal of Pathology, 2003
- Angiotensin II Type 1 (AT 1 ) Receptor–Mediated Accumulation of Angiotensin II in Tissues and Its Intracellular Half-life In VivoHypertension, 1997
- Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosisNature, 1996